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Abstract
Background: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) has high short-term mortality with
unknown causes. To predict this malignant condition in clinics is challenging. In this study, we aim to demonstrate
whether there are miRNAs that differ between AE-IPF and stable IPF, which may be served as reliable biomarker for
AE-IPF prediction.
Methods: Human fibrotic-associated miRNAs arrays were designed to detect miRNAs expression in plasma of 3 AE-
IPF patients, 3 Stable-IPF (S-IPF) patients and 3 normal controls (NC). Differentially expressed miRNAs between AE-IPF
and S-IPF patients were selected for further analyses. The validation studies were carried out in plasma of 12 AE-IPF
patients, 45 S-IPF patients and 51 healthy control subjects. Signaling pathways and cellular processes interacted with
validated miRNAs were predicted by DIANA-miRPath.
Results: According to the array analysis, 6 miRNAs showed differentiated expression between AE-IPF and S-IPF patients
(P < 0.05). In the validation studies, let-7d-5p was decreased in S-IPF and further decreased in AE-IPF, when compared
to NC (0.0003 ± 0.0002 vs 0.003 ± 0.002, P < 0.01 and 0.0007 ± 0.0005 vs 0.003 ± 0.002, P < 0.01). While miR-25-3p was
obviously decreased in S-IPF (0.0002 ± 0.0001 vs 0.0003 ± 0.0003, P < 0.01) but significantly increased in AE-IP (0.0023 ±
0.002 vs 0.0003 ± 0.0003, P < 0.01). In receiver-operator characteristic (ROC) curve analysis, the areas under the curve
(AUCs) of miR-25-3p and let-7d-5p were 0.83 and 0.75, respectively. The sensitivity at fixed specificity of 90% was
improved from 50% to 66.7% when the two miRNAs were combined. The functional prediction of miRNAs suggested
that the loss of anti-fibrotic capacity and the gain of uncontrolled cell growth may be required in AE-IPF pathogenesis.
Conclusions: In conclusion, miR-25-3p and let-7d-5p in plasma were differentially expressed between AE-IPF and S-IPF.
A combination of these two miRNAs may be a potential biomarker for AE-IPF from IPF.
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Background
Idiopathic pulmonary fibrosis (IPF) is a progressive dis-
ease with steady worsening of symptoms and gas ex-
change. Most patients die from respiratory failure within
3 years [1–3]. Although the clinical course of IPF is usually
gradual, but persistent, decline in lung function, some pa-
tients may experience an acute worsening of dyspnea and
lung function with an unknown etiology [2], and is typic-
ally defined as acute exacerbations (AE) of IPF. AE-IPF
may occur at any time during the disease course without
an identifiable cause [1]. Approximately 50% of IPF pa-
tients died from AE [4] with a poor prognosis and a me-
dian survival of less than 3 months [5]. Current treatment
strategies have consisted of high-dose corticosteroids,
which has no any data from controlled trials to prove their
efficacy for the patients of AE-IPF yet [5]. The pathological
feature by chest high resolution computed tomography
(HRCT) of AE-IPF is a diffuse alveolar damage superim-
posed on the usual interstitial pneumonia characteristics
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in IPF [6]. A better understanding of this disease is
desirable.
Mature miRNAs are endogenous 18–24 nucleotide
non-coding RNA molecules which act as posttranscrip-
tional regulators of gene expression and are stable in cir-
culation. The alterations of miRNAs in plasma or serum
have been served as improved and noninvasive biomarkers
for numerous pathological conditions, including cancers,
autoimmune diseases and tissue injury [7–9]. Over the
past years, molecular analysis of lung tissue resected for
diagnostic purposes have provided more encouraging re-
sults that suggest that IPF lung biopsies have a unique
mRNA transcriptome compared with non-fibrotic control
biopsy samples [10, 11]. More recently, much effort has
been made to define biologically relevant transcriptional
differences in IPF patients with distinguishable disease
progressions [10, 12]. Several studies have demonstrated
that serum miRNAs were differentially expressed in IPF
patients with rapidly or slowly progressive groups [13, 14].
However, it is unknown whether differentially expressed
miRNAs in the circulation is associated with AE-IPF.
In this retrospective study, we initially compared the hu-
man fibrosis-related miRNAs between S-IPF and AE-IPF.
Moreover, through a validation study in an expanded co-
hort, we determined the predictive role of the miRNAs in
distinguishing between S-IPF and AE-IPF.
Methods
Study population
The diagnosis of IPF was recommended by the American
Thoracic Society and the European Respiratory Society
(ATS\ERS)[15] and was previously described [16].
The diagnosis of AE-IPF was made according to the
proposed diagnostic criteria that mainly focus on a pre-
vious or concurrent diagnosis of IPF with a worsening of
its clinical manifestations over 30 days or less, and the
absence of infection or another identifiable etiology such
as left heart failure, or pulmonary embolism [17].
A total of 63 IPF patients were admitted to Drum
Tower Hospital from January 1, 2013 to June 30, 2014.
Among them, 15 patients were diagnosed as AE-IPF and
died within 1 month after the diagnosis. And 48 IPF pa-
tients with the stable radiographic findings and without
a worsening of their clinical manifestations over a period
of 30 days were defined as S-IPF. These S-IPF patients had
no acute exacerbation during the follow-up period of 1–
2.5 years after enrollment. In addition, 54 unrelated age-
matched healthy individuals were enrolled without current
or prior history of lung diseases in this study at the Center
of Physical Examination of Drum Tower Hospital.
This study was approved by the Ethical Committee of
the Affiliated Drum Tower Hospital of Nanjing University
Medical School.
Imaging studies
Chest HRCT was performed using various CT scanners
with the patients in suspended inspiration. The criteria
for inclusion of IPF in the study described previously [16].
Chest HRCT for AE-IPF generally demonstrated bilateral
ground-glass abnormality with or without areas of consoli-
dation, superimposed on the UIP pattern described previ-
ously [2]. Two radiologists, without knowledge of any of
the clinical, functional, and radiographic findings, inde-
pendently reviewed the HRCT of all patients.
Plasma miRNAs preparation
Blood samples were obtained once the patients were di-
agnosed as S-IPF or AE-IPF. About 5 ml venous blood
samples were collected in EDTA-containing tubes. Blood
samples were centrifuged within 1 h in two steps. Firstly,
all samples were centrifuged at 800 g for 10 min at 4 °C,
and the supernatants were collected into new RNase-
free tubes for a second centrifugation at 12,000 g for
10 min at 4 °C. The supernatants were then stored for
RNA extraction.
Plasma total RNA including miRNAs were extracted
with miRNeasy Serum/Plasma Kit (Qiagen) from 400ul
plasma samples according to the manufacturer’s instruc-
tions. 100pmol/L synthesized cel-miR-39 was added into
plasma as an internal calibrator to monitor extraction ef-
ficiency. The concentration and purity of the total RNA
were measured by Nanodrop 2000.
miRNAs array procedure
96-well miRNA expression profiles were used for 3 AE-
IPF, 3 Stable-IPF(S-IPF) and 3 normal controls (NC).
The array was designed according to miScript miRNA
PCR Array (MIHS-117Z, Qiagen) including 84 human
fibrosis-associated miRNAs, an external reference cel-
miR-39 and an internal reference U6. First, reverse tran-
scription (RT) of the total RNA samples was performed
with TaqMan miRNA Multiplex Reverse Transcription
Kit (Applied Biosystems) according to its protocol. Next,
quantitative real time PCR was performed according to
the protocol of TaqMan Universal PCR master mix (Ap-
plied Biosystems) on Step One plus PCR system (Ap-
plied Biosystems).
Quantitative RT-PCR (qRT-PCR) for plasma miRNAs
validation
Total miRNAs were extracted from 400 μl plasma of
additional 12 AE-IPF patients, 45 S-IPF patients, as well
as 51 healthy controls with PARIS Kit (Ambion), mixed
with 100pmol/L synthesized cel-miR-39 as an internal
calibrator to monitor extraction efficiency, and were dis-
solved in 50 μl elution buffer. Total miRNAs were re-
verse transcribed into a final volume of 30 μL cDNA
with specific primers (Roche) using Prime Script RT-
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PCR Kit (Takara) according to the instructions. Finally,
quantitative PCR was performed with UPL probe kit
(Roche) using Step One plus PCR system (Applied Bio-
systems). The reaction conditions were: 95 °C for
10 min, and 40 cycles of 95 °C for 15 s followed by 60 °
C for 1 min. Each sample was detected three times.
MiRNAs target prediction and pathway analysis
DIANA miRPath v.2.0 was used to predict target genes by
one or more miRNAs into known KEGG pathways [18].
The graphical output of the program provides an overview
of the parts of the pathway modulated by validated miR-
NAs. The statistical significance value associated with the
identified signaling pathways and biological process was
calculated by the program.
Statistical analysis
For the miRNA array and validation data analyses, the raw
expression levels were determined by the cycle number at
a predetermined threshold cycle (CT) <35. The fold-
change for each miRNA from the control group to each
patient group was calculated as 2-ΔΔCT with miR-16 as a
reference miRNA. Relative Concentrations of miRNAs in
AE-IPF, S-IPF and control plasma samples were calculated
as 2-ΔCT and compared by the T- test. Receiver-operator
characteristic (ROC) curve was generated under the non-
parametric distribution assumption for expression levels
of plasma miRNAs of AE-IPF and S-IPF patients by plot-
ting sensitivity% vs (100%-specificity %). Areas under the
curves (AUCs) were calculated. The biomarkers were con-
sidered to be useful when the value of AUCs were >0.7.
Logistic regression was used in the combined markers
analysis. All statistical analysis was performed with either
SPSS17.0 or GraphPad Prism5.0 Software. 95% confidence
intervals were used to quantify uncertainty, and P values
< 0.05 were considered to be statistically significant.
Results
Patient characteristics
Characteristics of patients and controls including
age, gender, results of lung function tests were de-
tailed in Table 1.
Identification of pulmonary fibrosis progress-related miR-
NAs in plasma
We initially profiled the expression of 84 fibrosis-related
miRNAs in the plasma of 3 AE-IPF patients, 3 S-IPF pa-
tients and 3 healthy controls by the fibrosis-specific
miRNAs arrays. With setting a threshold of CT < 35, a
total of 34 miRNAs were further analyzed. As shown in
the heat map (Fig. 1), the levels of the majority of miR-
NAs detected in this study were decreased in both AE-
IPF and S-IPF patients, when compared to that of the
controls. Among them, miR-132-3p and let-7d-5p were
further decreased in AE-IPF patients when compared to
that of S-IPF patients (p < 0.05). To identify the miRNAs
that were deferentially expressed miRNAs between AE-
IPF and S-IPF patients, we further compared the expres-
sions of the miRNAs in these two fibrotic groups to the
Table 1 Characteristics of study subjects













Agea, mean ± SD 64.3 ± 13.0 63.7 ± 9.7 64.0 ± 12.0 63.9 ± 11.7 63.6 ± 12.5 65.9 ± 9.7
Female/Male 1/2 1/2 1/2 18/27 5/7 19/32
FVCa (% predicted), mean ± SD 63.7 ± 17.2 NAb NA 65.7 ± 10.7 NAb NA
DLCO
a (% predicted), mean ± SD 56.3 ± 19.1 NAb NA 51.2 ± 17.7 NAb NA
FVC forced vital capacity, DLCO diffusion capacity for carbon monoxide of lung, NA not available
aValues were collected at the diagnosis. bpatients were unable to be tested
Fig. 1 Heatmap of the expressions of miRNAs in plasma of AE-IPF, S-
IPF and healthy control. Data were shown in 2-ΔΔCT. Red indicates
miRNAs induced and green indicates miRNAs repressed. AE1, AE2,
AE3 represent AE-IPF samples. S1, S2, S3 represent S-IPF samples. C1,
C2, C3 represent control samples. * means p < 0.05
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control group. We found that miR-31-5p and miR-338-
5p were up-regulated in S-IPF patients (p < 0.05), but
down-regulated in AE-IPF patients (p < 0.05), while miR-
25-3p and miR-92-3p were up-regulated in AE-IPF
group, but down-regulated in S-IPF group. All the above
miRNAs were selected for further validation.
Validation of differentially expressed miRNAs between
AE-IPF and S-IPF
Concentrations of the 6 miRNAs were detected in add-
itional 12 AE-IPF and 45 S-IPF patients, as well as 51
healthy controls by using RT-qPCR. We found that 4 of
them, miR-132-3p, miR-338-5p, miR-92-3p and miR-31-
5p, were not differentially expressed between AE-IPF
and S-IPF groups (data not shown). As been shown in
Fig. 2 and Table 2, the level of let-7d-5p was significantly
decreased in AE-IPF patients, when compared to those
of S-IPF patients (p < 0.05) and controls (p < 0.01). Inter-
estingly, in the same comparison, miR-25-3p was found
to be significantly decreased in S-IPF group (p < 0.01),
but increased greatly in AE-IPF group (p < 0.01).
ROC analysis
To evaluate the effectiveness of the two miRNAs for pre-
dicting AE-IPF patients among IPF patients, ROC curves
were constructed by comparing plasma measurements of
let-7d-5p and miR-25-3p in the AE-IPF patients with that
in the S-IPF patients. The diagnostic accuracy of the two
miRNAs for AE-IPF prediction was calculated (Fig. 3 and
Table 2). The AUCs of miR-25-3p and let-7d-5p were
0.831 and 0.752, respectively. The two candidate markers
were then subject to logistic regression analysis to
optimize the diagnostic utility. The sensitivity at fixed spe-
cificity of 90% was improved from 50 to 66.7%.
Signaling pathways prediction
DIANA-mirPath analysis was applied to predict the bio-
logic targets and pathways as well as cellular processes
that miR-25-3p and let-7d-5p affected. We found that
the two miRNAs shared no common direct targets at
transcriptional levels. We then investigated the cellular
processes interacted with miR-25-3p and let-7d-5p. We
found the intersections between the two miRNAs in cell
cycle related processes in an opposite way, while let-7d-
5p showed the suppressive effects on these processes,
miR-25-3p promoted (Table 3). Targets of miR-25-3p in-
volved in TP53, BCL2L11 and CDKN1C, etc. The ex-
pressions of these genes were predicted to be down-
regulated by miR-25-3p in AE-IPF, which suggested a
proliferative potential of cells. On the other hand, the
targets of let-7d-5p included TGFBR1 and CDK6. The
expressions of these genes were predicted to be up-
regulated in AE-IPF, which also suggested the probability
of cells growth.
Discussion
During the last decade, several studies have explored
biomarkers for the prediction of rapid progressive IPF
[13, 14, 19–21]. Still, AE-IPF is a less characterized
condition with unidentified causes and no tools for the
Fig. 2 Concentration of miR-25-3p and let-7d-5p in plasma of AE-IPF, S-IPF and healthy controls. The dash presents the mean value. NC, healthy
controls. * means p < 0.05. ** means p < 0.01
Table 2 Diagnostic sensitivities of measurements of single markers for predicting AE-IPF at predefined specificities
Relative concentration to miR-16 (mean ± SD) AUC(95% CI) Sensitivity at 90% Specificity
AE-IPF (n = 12) S-IPF (n = 45) NC (n = 51)
miR-25-3p 0.0023 ± 0.0020 0.0002 ± 0.0001 0.0003 ± 0.0003 0.83 (0.70–0.96) 50%
let-7d-5p 0.0003 ± 0.0002 0.0007 ± 0.0005 0.003 ± 0.002 0.75 (0.59–0.91) 50%
miR-25-3p + let-7d-5p — — — 0.83 (0.69–0.97) 66.7%
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prediction. Current study offers an opportunity to ap-
preciate circulating miRNAs detection as a newer stan-
dardized tool for prediction of AE-IPF.
In line with previous studies [13, 14], we found that
let-7d-5p expression was decreased in the plasma of S-
IPF and further decreased in AE-IPF. We were also able
to show that miR-25-3p was down-regulated in S-IPF,
but significantly up-regulated in AE-IPF, a new observa-
tion that indicates that S-IPF and AE-IPF are indeed
separable molecularly. As a single biomarker, the AUC
of miR-25-3p or let-7d-5p was 0.831 or 0.752 respect-
ively, and the sensitivity of the combination of the two
at fixed specificity of 90% was significantly improved, ar-
guing a beneficial potential with the combination of the
two miRNAs in AE-IPF determination, although the
AUC value of the current combination of the miRNAs
isolated in our study is still relatively low. Further stud-
ies involve a larger AE-IPF cohort and a larger panel of
testing miRNAs are desirable in order to obtain an im-
proved AUC value. Since men and women are repre-
sented in the IPF population in different proportions, we
compared the levels of miR-25-3p and let-7d-5p in the
plasma of female and male patients in our study in both
fibrotic groups, and observed no significant differences
(data not shown).
The various functional studies on the two miRNAs, miR-
25-3p and let-7d-5p, should not be neglected. First, a reduc-
tion of let-7d in epithelial cells causes epithelial-
mesenchymal transition and over-expression of let-7d in fi-
broblasts can reduce their mesenchymal properties [22, 23],
suggesting that the effect of let-7d is pro-fibrotic, a process
occurring in both S-IPF and AE-IPF, but significantly en-
hanced in latter. On the other hand, miR-25 has been found
to be increased in various cancers and may act as an onco-
miRNA [24–28]. The specific large increase of miR-25-3p in
AE-IPF, but reduced in S-IPF, suggested that the disease
may have gained a pro-growth condition. Our findings have
etiological implications that acute exacerbation in IPF may
be due to the collapse of anti-fibrosis mechanisms and the
gain of tumorigenic molecular tendency locally or systemic-
ally. Whether the two processes are parallel or mutually
interacted is not known. More importantly, whether AE-IPF
may obtain a neoplastic disease-like alteration is extremely
provoking, but needs cellular and pathological evidence.
Fig. 3 ROC curve analyses of plasma miR-25-3p and let-7d-5p as single markers and combined markers for predicting AE-IPF from IPF. a ROC
curve of miR-25-3p as a single biomarker for predicting AE-IPF from IPF. b ROC curve of let-7d-5p as a single biomarker for predicting AE-IPF from
IPF. c ROC curve of combination of miR-25-3P and let-7d-5pas a biomarker for predicting AE-IPF from IPF
Table 3 The intersected biologic pathways of miR-25-3p and let-7d-5p predicted by KEGG pathways analysis
KEGG pathway p-value let-7-5p interacted genes miR-25-3p interacted genes
Glioma 9.30E-06 IGF1R,KRAS,CDK6,PDGFA TP53
Melanoma 6.97E-05 IGF1R,KRAS,CDK6,PDGFA TP53
Chronic myeloid leukemia 0.0002533 IGF1R,KRAS,CDK6 TP53
Cell cycle 0.0017125 ESPL1,CDK6,BUB3,CDC25A TP53,CDKN1C
Colorectal cancer 0.0034595 TGFBR1,BCL2,KRAS TP53
PI3K-Akt signaling pathway 0.0043839 THBS1,BCL2,IGF1R,KRAS,CDK6,PDGFA TP53,BCL2L11
Hepatitis B 0.0043839 TGFBR1,BCL2,KRAS,CDK6 TP53
Pancreatic cancer 0.0049791 IGF1R,KRAS,CDK6 TP53
Bladder cancer 0.0050961 TGFBR1,KRAS TP53
Non-small cell lung cancer 0.0060073 KRAS,CDK6 TP53
HTLV-I infection 0.0083159 TGFBR1,KRAS,BUB3,ADCY9,PDGFA TP53, AT2B
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Interestingly, two genes, ATP11A and OBFC1 found
to be associated with IPF susceptibility in a GWAS study
[29] were predicted as targets of miR-25-3p. It will be
highly interesting to study the association between the
two genes and miR-25-3P in IPF pathogenesis. More-
over, it is known that the shortening of telomere length
is a risk factor for the survival of IPF [16, 30]. Whether
one could make a link between the shortening of telo-
mere length and the ill-expression of miRNAs in IPF
progression remains to be determined.
In addition to the patients enrolled from a single med-
ical center with a relatively small size in our study, one
weakness of this investigation is that the current study
was based on a scheme of one-time-point detection of
the miRNAs without longitudinal measurements due to
the clinical limitations, which may mask the relationship
between the dynamic expressions of the miRNAs and
the disease progression. Since the variability of the clin-
ical courses of IPF are widely ranged and might be het-
erogeneous [31], the identification of the predictors that
are capable of distinguishing the clinical courses of IPF
would be a great challenge. Nevertheless, our study may
have provided a clue to position miRNAs as the candi-
dates of AE-IPF predicators.
Conclusions
In this study, we reported that the human fibrosis-
related miRNAs, miR-25-3p and let-7d-5p, were differ-
entially expressed between S-IPF and AE-IPF. The combin-
ation of these two miRNAs was significant in predicting an
acute exacerbation of IPF. The result indicates that both
loss of tissue anti-fibrotic capacity and gaining of uncon-
trolled cell growth may be required in AE-IPF pathogenesis.
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